Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton’s tyrosine kinase inhibitors

Abstract

Bruton’s tyrosine kinase (BTK) is a key component of the B cell receptor (BCR) signaling pathway and plays a crucial role in B cell malignancies and autoimmune disorders; thus, it is an attractive target for the treatment of B cell related diseases. Here, we evaluated the BTK inhibitory activity of a series of pyrimido[4,5-d][1,3]oxazin-2-one derivatives. Combining this evaluation with structure-activity relationship (SAR) analysis, we found that compound 2 exhibited potent BTK kinase inhibitory activity, with an IC50 of 7 nM. This derivative markedly inhibited BTK activation in TMD8 B cell lymphoma cells and thus inhibited the in vitro growth of the cells. Further studies revealed that compound 2 dose dependently arrested TMD8 cells at G1 phase, accompanied by decreased levels of Rb, phosphorylated Rb, and cyclin D1. Moreover, following treatment with compound 2, TMD8 cells underwent apoptosis associated with PARP and caspase 3 cleavage. Interestingly, the results of the kinase activity assay on a small panel of 35 kinases showed that the kinase selectivity of compound 2 was superior to that of the first-generation inhibitor ibrutinib, suggesting that compound 2 could be a second-generation inhibitor of BTK. In conclusion, we identified a potent and highly selective BTK inhibitor worthy of further development.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. 1.

    Pal Singh S, Dammeijer F, Hendriks RW. Role of bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17:57.

  2. 2.

    Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E. Bruton’s tyrosine kinase (BTK) as a promising target in solid tumors. Cancer Treat Rev. 2017;58:41–50.

  3. 3.

    Rushworth SA, Pillinger G, Abdul-Aziz A, Rachel P, SM S, MM Y, et al. Activity of bruton’s tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells. Lancet Haematol. 2015;2:204–11.

  4. 4.

    Smith CI, Baskin B, Humiregreiff P, Zhou JN, Olsson PG, Maniar HS, et al. Expression of bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol. 1994;152:557–65.

  5. 5.

    Seiler T, Dreyling M. Bruton’s tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives. Expert Opin Invest Drugs. 2017;26:909–15.

  6. 6.

    Wu J, Zhang M, Liu D. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. Oncotarget. 2016;8:7201.

  7. 7.

    Coutre SE, Furman RR, Flinn IW, Burger JA, Blum K, Sharman J, et al. Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Cancer Res. 2017;23:1149–55.

  8. 8.

    Valla K, Flowers CR, Koff JL. Targeting the B cell receptor pathway in non-hodgkin lymphoma. Expert Opin Invest Drugs. 2018;27:513–22.

  9. 9.

    Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, et al. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia. 2017;32:960–70.

  10. 10.

    Ge C, Wang F, Cui C, Su X, KKW To, Wang X, et al. PCI29732, a bruton’s tyrosine kinase inhibitor, enhanced the efficacy of conventional chemotherapeutic agents in ABCG2-overexpressing cancer cells. Cell Physiol Biochem. 2018;48:2302–17.

  11. 11.

    Brown JR. Ibrutinib (PCI-32765), the first BTK (bruton’s tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malig Rep. 2013;8:1–6.

  12. 12.

    Rodgers TD, Reagan PM. Targeting the B-cell receptor pathway: a review of current and future therapies for non-hodgkin’s lymphoma. Expert Opin Emerg Dr. 2018;23:111–22.

  13. 13.

    Paydas S. Management of adverse effects/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56–63.

  14. 14.

    Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang YL, et al. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia. 2015;29:895–900.

  15. 15.

    Landau DA, Sun C, Rosebrock D, Herman SEM, Fein J, Sivina M, et al. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017;8:2185.

  16. 16.

    Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, et al. The addition of the BTK Inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res. 2016;22:2684–96.

  17. 17.

    Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating M, Wierda W, et al. Comparison of acalabrutinib, a selective bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res. 2017;23:3734–43.

  18. 18.

    Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of bruton tyrosine kinase. J Hematol Oncol. 2016;9:80.

  19. 19.

    Awan FT, Jurczak W. Use of acalabrutinib in patients with mantle cell lymphoma. Expert Rev Hematol. 2018;11:495–502.

  20. 20.

    Jurczak W, Dlugosz-Danecka M, Wang M. Acalabrutinib for adults with mantle cell lymphoma. Expert Rev Clin Pharmacol. 2019;12:179–87.

  21. 21.

    Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:21.

  22. 22.

    Barf T, Covey T, Izumi R, Kar B, Gulrajani M, Lith B, et al. Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase (BTK) inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363:240–52.

  23. 23.

    Hao YJ, Jian KL, Qu R, Sun DH, Zhao ZJ, Chen Z, et al. Structure-guided design of c4-alkyl-1,4-dihydro-2hpyrimido[4,5-d][1,3]oxazin-2-ones as potent and mutant-selective epidermal growth factor receptor (EGFR) L858R/T790M inhibitor. Sci Rep. 2017;7:1–13.

  24. 24.

    Bender AT, Gardberg A, Pereira A, Johnson T, Wu Y, Grenningloh R, et al. Ability of bruton’s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling. Mol Pharmacol. 2017;91:208–19.

  25. 25.

    Richard A, Friesner JLB, Murphy Robert B, Halgren Thomas A, Klicic Jasna J, Mainz Daniel T, et al. Glide: a new approach for rapid, accurate docking and scoring. J Med Chem. 2004;47:1739–49.

  26. 26.

    Liu ZC, Wang ZL, Huang CY, Fu ZJ, Liu Y, Wei ZC, et al. Duhuo jisheng decoction inhibits SDF-1-induced inflammation and matrix degradation in human degenerative nucleus pulposus cells in vitro through the CXCR4/NF-κB pathway. Acta Pharmacol Sin. 2018;39:912–22.

  27. 27.

    Zheng YD, Bai G, Tang C, Ke CQ, Yao S, Tong LJ, et al. 7α,8α-epoxynagilactones and their glucosides from the twigs of podocarpus nagi: isolation, structures, and cytotoxic activities. Fitoterapia. 2018;125:174–83.

  28. 28.

    Zhang XX, Lin J, Liang TZ, Duan H, Tan XH, Xi BM, et al. The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation. Acta Pharmacol Sin. 2019;40:98–110.

  29. 29.

    Shi JJ, Chen SM, Guo CL, Li YX, Ding J, Meng LH, et al. The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8. Acta Pharmacol Sin. 2018;39:1338–46.

  30. 30.

    Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, P.B. R, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88–92.

  31. 31.

    Yahiaoui A, Meadows SA, Sorensen RA, Cui ZH, Keegan KS, Brockett R, et al. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors. PLoS ONE 2017;12:221.

  32. 32.

    Kuo HP, Ezell SA, Hsieh S, Schweighofer KJ, Cheung LW, Wu S, et al. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. Am J Cancer Res. 2016;6:2489–501.

  33. 33.

    Dwivedi P, Muench DE, Wagner M, Azam M, Grimes HL, Greis KD, et al. Time resolved quantitative phospho-tyrosine analysis reveals bruton’s tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors. Leukemia. 2019;33:75–87.

  34. 34.

    Zhang Z, Zhang DG, Liu Y, Yang DZ, Ran FS, Wang ML, et al. Targeting bruton’s tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: preclinical and clinical developments of small molecule inhibitors. Arch Pharm. 2018;351:369.

  35. 35.

    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin. 2018;68:394–424.

  36. 36.

    Reiff SD, Muhowski EM, Guinn D, Lehman A, Fabian CA, Cheney C, et al. Non-covalent inhibition of C481S bruton’s tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib resistant CLL. Blood. 2018;132:1039–49.

  37. 37.

    Tissino E, Benedetti D, Herman SEM, Hacken ET, Ahn IE, Chaffee KG, et al. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med. 2018;215:681–97.

Download references

Acknowledgements

The research is supported in part by the National Key Research and Development Program (Grant 2016YFA0502304), the Special Program for Applied Research on Super Computation of the NSFC-Guangdong Joint Fund (the second phase) under grant No. U1501501, and the Fundamental Research Funds for the Central Universities.

Author information

MZL, PRS, DD, YYD, JD, and HIL designed the study; MZL, PRS, LJT, and TZ performed the research; DD and YYD  contributed the compound; MZL, PRS, DD, and YYD  analyzed the data; and MZL, PRS, DD, HIL, and HX  wrote the paper.

Correspondence to Hua Xie or Hong-lin Li or Jian Ding.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • B cell receptor
  • Bruton’s tyrosine kinase
  • ibrutinib
  • small-molecule inhibitor
  • B cell malignancies